<DOC>
	<DOCNO>NCT00672594</DOCNO>
	<brief_summary>The purpose study look blood tissue sample change follow use Sunitinib malate . Additionally , would like find drug , Sunitinib malate , safe work men prostate cancer . Sunitinib malate , also know Sutent , approve U.S. Food Drug Administration ( FDA ) , treatment tumor intestines kidney test research study use men prostate cancer .</brief_summary>
	<brief_title>Study Sunitinib Malate Patients With Newly Diagnosed Prostate Cancer Prior Prostatectomy</brief_title>
	<detailed_description>Eligible patient treat 50 mg daily four week follow one two week treatment prior undergoing radical prostatectomy . Patients palpable disease ( cT2-3 ) patient 3 positive prostatic biopsy one lobe may undergo additional study IFP monitoring treatment week 4 study treatment . Safety tolerability Sunitinib malate therapy dose schedule patient population assess . Extensive correlative science evaluation , include assessment physiologic , cellular , molecular genetic change treatment Sunitinib malate , perform</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic evidence adenocarcinoma prostate deem candidate curative RRP Intermediate high risk , clinically localized disease Adequate organ function Patients must surgically sterile must agree use effective contraception period therapy Select imaging rule metastasis do clinically indicate Signed date inform consent document Prior treatment prostate cancer Major surgery radiation therapy within 4 week start study treatment NCI CTCAE grade 3 hemorrhage within 4 week start therapy History know metastatic prostate cancer Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias NCI CTCAE grade 2 great QTc interval &gt; 500 msec baseline EKG Hypertension control medication ( &gt; 150/100 mm Hg despite optimal medical therapy ) . Preexisting thyroid abnormality thyroid function maintain normal range medication Known active infection Concurrent treatment another clinical trial . Supportive care trial nontreatment trial , e.g . QOL , allow . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>